Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study

Guo, Xiaofeng; Zhai, Jing; Wei, Qianqian; Twamley, Elizabeth W.; Jin, Hua; Fang, Maosheng; Hu, Maorong; Zhao, Jingping

doi:10.1016/j.neulet.2011.08.027

Cited by 32 publications

(31 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies assessing effectiveness were made up of RCTs (n=3),19–21 nonrandomized open-label studies (n=2),22,23 observational studies (n=2),24,25 a cross-sectional comparative study,26 and a cohort study 27. The mean duration of these studies was 37 weeks (median 52, range 12–52) and the mean number of enrolled patients was 690.3 (median 698, range 60–1,227).…”

Section: Resultsmentioning

confidence: 99%

“…Assessment of neurocognitive function was the primary objective of two studies 19,23. In a placebo-controlled RCT of 129 patients with first-episode schizophrenia, patients treated with olanzapine experienced significantly improved short-term memory, immediate memory, and memory quotient as assessed by the Wechsler Memory Scale (Fourth Edition) over a 12-week period compared with placebo (n=132, P <0.01) 19.…”

Section: Resultsmentioning

confidence: 99%

“…In a placebo-controlled RCT of 129 patients with first-episode schizophrenia, patients treated with olanzapine experienced significantly improved short-term memory, immediate memory, and memory quotient as assessed by the Wechsler Memory Scale (Fourth Edition) over a 12-week period compared with placebo (n=132, P <0.01) 19. In one naturalistic study, 698 analyzable patients with early-stage schizophrenia received olanzapine, chlorpromazine, sulpiride, clozapine, risperidone, quetiapine, or aripiprazole monotherapy 23. Neurocognitive tests including the Wechsler Memory Scale-Revised Visual Reproduction Test, Wechsler Adult Intelligence Scale-Revised Digit Symbol Test, Computerized Wisconsin Card Sorting Test (128-card version), Trail Making Tests, and the Wechsler Adult Intelligence Scale-Revised Digit Span Test assessed aspects such as attention and memory, and was administered at baseline, 6 and 12 months.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review

Xue

Liu

Zhang

et al. 2014

NDT

View full text Add to dashboard Cite

BackgroundDespite the burden of schizophrenia and bipolar disorder in the Chinese population, country-specific data to guide practitioners regarding antipsychotic therapy are lacking. The primary aim of this systematic review was to examine evidence of the efficacy, effectiveness, and safety of olanzapine in Chinese populations.MethodsA systematic literature search was conducted using databases covering international and Chinese core journals using search terms related to schizophrenia and bipolar disorder, specified countries (People’s Republic of China, Hong Kong, Taiwan), and olanzapine treatment. Following initial screening, inclusion and exclusion criteria were applied to the search results to identify relevant studies from which data were extracted.ResultsA total of 489 publications were retrieved and 61 studies were identified for inclusion. Most studies were related to schizophrenia (n=54), with six studies related to bipolar disorder and one study related to both conditions. The quality of study methods and reporting in international journals was noticeably better than in Chinese language journals. Most studies included relatively small patient populations and were of short duration. The efficacy of olanzapine in Chinese populations was confirmed by multiple comparative and noncomparative studies that found statistically significant reductions in symptom measures in studies conducted for ≥6 weeks (schizophrenia) or ≥3 weeks (bipolar disorder). Findings related to effectiveness (treatment discontinuation, quality of life, and neurocognitive improvements) were generally consistent with those observed in non-Chinese populations. No new safety signals specific for Chinese populations were raised for olanzapine.ConclusionChinese and non-Chinese populations with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses. Differences between these populations, especially in relation to the relative efficacy of olanzapine versus other antipsychotics, may warrant further investigation via studies incorporating both populations. Use of local data to provide evidence for practice guidelines should be encouraged, and may promote ongoing improvements in the quality of research and study reporting.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review

Xue

Liu

Zhang

et al. 2014

NDT

View full text Add to dashboard Cite

show abstract

“…Keefe et al [34] reported significant improvement with olanzapine and risperidone in some but not all cognitive domains, and yet markedly greater improvement in verbal learning and memory with haloperidol, compared to these two AAPDs, a unique finding to our knowledge, greatly affecting the composite scores for the three drugs. Another example of heterogeneity in response is a large 12 month open trial in early stage schizophrenia, of chlorpromazine, a typical APD, and sulpiride, a substituted benzamide with some features of both a typical and AAPD, and five AAPDs, aripiprazole, clozapine, olanzapine, quetiapine and risperidone, which found significant superiority for olanzapine and quetiapine, but not the other AAPDs, in composite score and speed of processing, compared to chlorpromazine and sulpiride [35 ]. Unfortunately, like most CIS, studies, they did not report the percentages of patients who experience improvement that would be expected to be clinically significant, and beyond practice levels, 0.5 or 1.0 SD, respectively [36].…”

Section: Introductionmentioning

confidence: 99%

Pharmacotherapy of cognition in schizophrenia

Meltzer

2015

Current Opinion in Behavioral Sciences

View full text Add to dashboard Cite

“…Unfortunately, the available treatments show little effect on these symptoms [10]. Antipsychotics, in general, seem to have modest efficacy on cognition [11]. Moreover, despite the hopes placed in the second-generation antipsychotics, the CATIE [12] and EUFEST [13] studies, despite their limitations, showed no significant differences between antipsychotics of first and second generations.…”

mentioning

confidence: 99%